George R. Simon, MD, FACP, FCCP

George R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses how the introduction of immunotherapy in the treatment of patients with locally advanced, stage III non–small cell lung cancer (NSCLC) has affected prognosis.

George R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.